Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 31, 1951-1954, December 1, 1971]
© 1971 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flesher, J. W.
Right arrow Articles by Sydnor, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flesher, J. W.
Right arrow Articles by Sydnor, K. L.

Carcinogenicity of Derivatives of 7,12-Dimethylbenz(a)anthracene1

James W. Flesher and Katherine L. Sydnor

Departments of Pharmacology and Medicine, University of Kentucky College of Medicine, Lexington, Kentucky 40506

Eleven derivatives of 7,12-dimethylbenz(a)anthracene were tested for carcinogenicity in Sprague-Dawley female rats by the s.c. injection of 1.0 or 0.1 mg of compound dissolved in 0.1 ml of sesame oil on alternate days for 20 doses. Eight derivatives [7-hydroxymethyl-12-methyl-, 7-formyl-12-methyl-, 7-methoxymethyl-12-methyl-, 7-acetoxymethyl-12-methyl-, 7-benzoyloxymethyl-12-methyl-, 7-iodomethyl-12-methyl-, 7-bromomethyl-12-methyl,- and 7-chloromethyl-12-methylbenz(a)anthracene] were carcinogenic at the 1-mg dose level, and 5 [benzoyloxymethyl-12-methyl-, 7-formyl-12-methyl-, 7-bromomethyl-12-methyl-, 7-hydroxymethyl-12-methyl-, and 7-iodomethyl-12-methylbenz(a)anthracene] were carcinogenic at the 0.1-mg dose level (200 days of observation). These observations suggest that the formation of 7-hydroxymethyl-12-methylbenz(a)anthracene may be the first step in the chain of events which result in cancer caused by these polycyclic hydrocarbons.

1 Supported by Grant E307 from the American Cancer Society and presented in part at the Tenth International Cancer Congress, Abstracts, No. 92, p. 60, Houston, Texas, 1970.

Received 5/ 5/71. Accepted 7/21/71.




This article has been cited by other articles:


Home page
ScienceHome page
T Watabe, T Ishizuka, M Isobe, and N Ozawa
A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[alpha]anthracene
Science, January 22, 1982; 215(4531): 403 - 405.
[Abstract] [PDF]


Home page
ScienceHome page
D. M. Jerina and J. W. Daly
Arene Oxides: A New Aspect of Drug Metabolism
Science, August 16, 1974; 185(4151): 573 - 582.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1971 by the American Association for Cancer Research.